The new formulation targets internal and external parasites, expanding the BRAVECTO^® portfolio

RAHWAY, N.J., November 26, 2024 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Commission has granted the marketing authorization for BRAVECTO® TriUNO, a new formulation of BRAVECTO (fluralaner) for dogs that targets both internal and external parasites. The three-in-one chewable tablet will be available through licensed veterinarians. The product has also been approved by regulatory agencies in Peru, Guatemala, Nicaragua, and Costa Rica.

BRAVECTO TriUNO is approved for the treatment of tick and flea infestations in dogs providing immediate and persistent flea (Ctenocephalides felis and C. canis) and tick (Dermacentor reticulatus, Ixodes hexagonus, I. ricinus, and Rhipicephalus sanguineus)killing activityfor one month, for the treatment of infections with gastrointestinal nematodes of the following species: roundworms (adult stages of Toxocara canis, and adult stages of Toxascaris leonina)and hookworms (L4, immature adult (L5), and adult stages of Ancylostoma caninum and adult stages of Uncinaria stenocephala), for the prevention of heartworm disease (caused by Dirofilaria immitis), and for the prevention of angiostrongylosis (by reduction of the level of infection with immature adult (L5) and adult stages of Angiostrongylus vasorum).

Since its introduction in 2014, BRAVECTO has provided long-lasting flea and tick protection, with more than 350 million doses distributed in 100 countries. BRAVECTO is available in a variety of formulations, including products for both dogs and cats.

“Merck Animal Health is committed to enabling more convenient options for comprehensive parasitic protection for pets and their owners,” said Jason Drake, DVM, DACVM-Parasitology director, scientific marketing affairs, Global Companion Animal Parasiticides, Merck Animal Health. “This new addition to our BRAVECTO portfolio provides easy-to-administer protection for pets against a broader range of parasites. While most pet owners understand the importance of protection against fleas and ticks, it’s equally important to protect pets from internal parasites as both can lead to further health issues and disease. With a single medication, pet owners can feel assured their pets are protected from all sides.”

BRAVECTO TriUNO is available as a flavored chewable tablet indicated for dogs and puppies from 8 weeks of age and at least 1.27 Kg body weight and can be administered monthly to dogs at risk of infestation by multiple types of internal and external parasites.  It contains three anti-parasitic ingredients including fluralaner, which provides activity against ticks and fleas, moxidectin, which provides systemic activity against a range of external systemic and internal parasites, and pyrantel, which provides activity against a variety of internal parasites.

BRAVECTO TriUNO treats existing fleas and ticks on dogs fast following treatment and continues to kill newly acquired fleas and ticks for an entire month following treatment. Additionally, roundworms and hookworms are the most common canine intestinal parasites and are also effectively treated with BRAVECTO TriUNO. Heartworm and lungworm threats are expanding into new areas and are becoming more common. Mosquitoes transmit heartworm from dog to dog, and lungworm is transmitted to dogs by slugs and snails

About Merck Animal Health

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals^®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, X (formerly Twitter) and Instagram.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).